Related Experiment Video
Updated: Jan 8, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
Thyroid dysfunction in non-alcoholic fatty liver disease: A case-control study
Harshit Malkan1, Bhavita Patel2, Mahesh G Solu1
1Department of General Medicine, Dr. Kiran C Patel Medical College and Research Institute, Bharuch, Gujarat, India.
None:
Non-alcoholic fatty liver disease (NAFLD) is increasingly recognized as a hepatic manifestation of metabolic dysfunction, with emerging evidence linking it to thyroid abnormalities. In this case-control study of 120 adults, thyroid dysfunction was more prevalent in NAFLD cases, with 20% having overt hypothyroidism and 5% subclinical hypothyroidism. Thyroid dysfunction increased with NAFLD severity, with overt hypothyroidism observed in 66.7% of Grade 3 cases. These findings highlight a strong association between worsening thyroid function and NAFLD severity, suggesting the need for routine thyroid screening in NAFLD management.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Synthesis and Regulation of Thyroid Hormones
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...

